Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

6 terminated/withdrawn out of 9 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

6 terminated

Enrollment Performance

Analytics

Phase 1

7(77.8%)

Phase 2

2(22.2%)

9Total

Phase 1(7)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01018069Phase 2Terminated

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Role: lead

NCT00768339Phase 1Terminated

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Role: lead

NCT00882869Phase 1Completed

XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Role: lead

NCT00891683Phase 2Completed

Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy

Role: lead

NCT00558545Phase 1Terminated

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Role: lead

NCT00557596Phase 1Terminated

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Role: lead

NCT00363974Phase 1Completed

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

Role: lead

NCT00558922Phase 1Terminated

A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

Role: lead

NCT00385775Phase 1Terminated

Study of XIAP Antisense for Advanced Cancers

Role: lead

All 9 trials loaded